PSMA-targeted radiopharmaceutical therapy has emerged as a novel treatment modality for patients with metastatic castration-resistant prostate cancer, a stage of disease in which the cancer continues to progress despite standard therapies. The strategy was studied extensively in the VISION clinical trial, and in 2022, 177Lu-PSMA-617 became the first radiopharmaceutical therapy approved to treat prostate cancer, marking a milestone for nuclear medicine and molecular imaging. Approval, however, rested on evidence gathered in a selected trial population, and clinicians have since faced practical questions about how the therapy performs among the broader and more diverse groups of patients encountered in routine practice, including those who are older, more heavily pretreated, or whose disease patterns differ from the trial enrollment criteria.

“Although the VISION clinical trial demonstrated the safety and efficacy of 177Lu-PSMA-617 in a selected population, there is a need for complementary real-world data to understand its use and outcomes in routine clinical practice among broader and more diverse patient populations,” said Clément Bailly, MD, PhD, a nuclear medicine physician at Nantes University Hospital in France. “France’s early-access program provided a valuable opportunity to evaluate the safety and efficacy of 177Lu-PSMA-617 in a real-world setting.” The program offered exactly that opportunity at unusual scale, enrolling patients from December 2021 to April 2025 and generating systematic data on treatment exposure, efficacy outcomes, and safety findings drawn directly from routine clinical practice rather than from a protocol-driven trial environment.

Every participant in the program had metastatic castration-resistant prostate cancer with progressive disease after receiving at least one standard treatment. Through the early-access program, patients received up to six cycles of 177Lu-PSMA-617. During regular follow-up, clinicians collected clinical evaluations, prostate-specific antigen, or PSA, status, imaging assessments, and treatment-related adverse events. The researchers then assessed progression-free survival and overall survival and compared the results directly with those observed in the VISION trial. The design created one of the most detailed real-world portraits of a radiopharmaceutical therapy assembled to date, covering not only how patients fared but also how treatment patterns shifted across dozens of centers over more than three years of enrollment.

The comparison revealed a cohort that was, in several respects, more challenging than the trial population that anchored the drug’s approval. Patients in the early-access program were older, more heavily pretreated, and had more lymph node metastases than those in VISION, although they also presented with lower baseline PSA values. Despite these differences, the outcomes held remarkably steady. Median progression-free survival in the French cohort was 7.6 months, compared with 8.7 months in VISION, a modest difference in the context of a population with more advanced disease and more extensive prior treatment. Disease control, measured according to PSA criteria, was achieved in 82 percent of the French cohort, indicating that the large majority of patients derived a measurable biochemical response to therapy in ordinary clinical conditions.

Beyond the headline numbers, the scale of the program allowed the investigators to characterize patterns that smaller series could not resolve with confidence. Subgroup analyses confirmed that the therapy remained effective in older patients, a group often underrepresented in pivotal trials, and showed more favorable outcomes among patients who had been less heavily pretreated with taxane-based chemotherapy. That latter observation carries practical weight for treatment sequencing, because it suggests that the extent of a patient’s prior treatment at the time radiopharmaceutical therapy begins, rather than age alone, is associated with how much benefit the treatment can deliver. The safety profile proved manageable even in older and heavily pretreated individuals, consistent with the outcomes reported in the VISION trial.

The analysis also documented a phenomenon that clinicians managing the therapy in practice will recognize: a flare-up effect. Some patients experienced PSA progression after the first cycle of 177Lu-PSMA-617, only to show a PSA decline after the second cycle. The finding, documented systematically across the cohort, adds to the clinical understanding of how PSA values can behave in the early phase of radiopharmaceutical therapy and illustrates the kind of treatment-related pattern that large real-world datasets are well positioned to capture. For a therapy whose monitoring relies heavily on PSA trends and imaging assessments, having routine-practice data on such patterns adds context to the follow-up decisions that clinicians make cycle by cycle.

Perhaps the most telling signal in the data concerns how clinical practice itself evolved during the program. Over time, clinicians progressively treated patients with less advanced disease and lower levels of prior treatment exposure, suggesting that as experience with radiopharmaceutical therapy accumulated, providers became more comfortable incorporating it earlier in the treatment journey. That drift toward earlier use, visible in the treatment patterns of 46 centers across France, reflects a growing confidence in the therapy’s tolerability and effectiveness as documented in this cohort. It also demonstrates the value of early-access frameworks as a source of practice-based evidence: the same program that delivered the therapy to patients simultaneously recorded how its use changed as clinical familiarity grew.

“This real-world data confirms that the benefits seen in the VISION trial translate into routine clinical practice,” said Guilhem Roubaud, MD, a medical oncologist at Institut Bergonié in Bordeaux, France. “For patients with advanced prostate cancer, this study means earlier access to a potentially life-extending treatment when options are limited, adding value to the French Early Access program in delivering both rapid access to innovation and robust evidence to inform future clinical practice for patients and healthcare decisions whenever possible.” His comments frame the dual contribution of the program: it accelerated patient access to a newly approved therapy while generating the practice-based evidence needed to inform its wider use.

For patients with metastatic castration-resistant prostate cancer, a disease in which options narrow after standard therapies are exhausted, the findings support the use of 177Lu-PSMA-617 in routine care for a broad range of individuals, including patients eligible for retreatment and those who may benefit from earlier use in the course of the disease. The consistency between the trial and real-world results, achieved in a population that was older and more heavily treated than the trial cohort, addresses one of the central uncertainties that accompanies any new cancer therapy as it moves from study settings into clinics. As radiopharmaceutical therapy takes its place alongside hormonal treatments and chemotherapy in the prostate cancer arsenal, the French experience stands as the largest real-world confirmation to date that the benefits measured in the VISION trial extend to the diverse patients treated in everyday practice.

Subject of Research: Real-world outcomes of 177Lu-PSMA-617 radiopharmaceutical therapy in metastatic castration-resistant prostate cancer

Article Title: Real-world results confirm benefit of PSMA therapy for prostate cancer

Article References: Real-world results confirm benefit of PSMA therapy for prostate cancer. Original publication (Bibliographic details unavailable.)

Image Credits: AI Generated

DOI: Not provided

Keywords: prostate cancer, PSMA therapy, 177Lu-PSMA-617, radiopharmaceutical therapy, metastatic castration-resistant prostate cancer, VISION trial, real-world evidence, French early-access program, nuclear medicine, progression-free survival, The Journal of Nuclear Medicine, SNMMI